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ABSTRACT (no more than 150 words) 
Abnormal uterine bleeding (AUB) is a common and chronic condition, affecting women 
throughout their reproductive years. The FIGO PALM-COEIN classification system, 
facilitates understanding of possible AUB aetiology, and allows for characterisation of cause 
by use of universal terminology to describe menstrual disorders. There are a wide variety of 
medical and surgical (excisional and non-excisional) treatments available, but often women 
will choose a period of observation (conservative treatment), after sinister pathology is 
excluded. Management of AUB has to be tailored to the individual patient as the ultimate of 
goal is improvement in quality of life. 
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DEFINITIONS 
To understand abnormal uterine bleeding (AUB), we must first understand the variances of a 
normal menstrual cycle.  A “normal” menstrual cycle is defined based on four parameters 
(frequency, regularity, duration, or volume) summarised in Table 1.  The National Institute 
for Care and Excellence (NICE) recommends that heavy menstrual bleeding (HMB), a sub-
category of AUB should be recognised based on the impact it has on the woman’s quality of 
life (QoL), and all interventions must focus on improving QoL, rather than an objective blood 
loss measurement. 
[Insert Table 1] 
 
 
MENSTRUAL TERMINOLOGY AND THE NEED FOR A 
CLASSIFICATION SYSTEM – FIGO PALM COEIN SYSTEM 
The varied use of terminology to describe AUB symptoms has led to difficulties in many 
areas, including documenting symptoms; determining best medical and surgical treatments; 
design and interpretation of research data; and attempts to conduct multinational clinical 
trials. 
 
These concerns were addressed by the Menstrual Disorders Working Group within the 
International Federation of Gynecology and Obstetrics (FIGO), which subsequently became a 
standing committee, the Menstrual Disorders Committee (MDC).  The FIGO MDC was 
responsible for the menstrual terminology encouraged for use in clinical care and research 
today. In addition, the FIGO MDC also developed the PALM-COEIN acronym for sub-
classifying AUB aetiology.  Both FIGO systems have recently been further refined. 
 
 4 
 
ABNORMAL UTERINE BLEEDING (AUB) 
AUB was re-defined by (FIGO) in 2009 to introduce standardisation of nomenclature and 
identify an aetiological basis for AUB in the reproductive years. AUB is the overarching term 
used to describe any symptomatic variation from normal menstruation (in terms of frequency, 
regularity, duration, or volume) and also includes intermenstrual bleeding.  Table 2 
summarises the recommended terminology for women with AUB. 
[Insert Table 2] 
 
Acute AUB 
An episode of uterine bleeding in a woman of reproductive age, who is not pregnant, that is 
of sufficient quantity to require immediate intervention to prevent further blood loss. 
 
Chronic AUB 
Bleeding from the uterine body (or corpus), that is abnormal in frequency, regularity, 
duration, and/or volume, and has been present for at least the majority of the past six months. 
 
Intermenstrual bleeding 
When AUB occurs between well-defined cyclical menses, the symptom is called 
intermenstrual bleeding (IMB).  This symptom may be virtually impossible to discern if the 
woman has irregular and/or very frequent menses.  
 
These may be further sub divided as  
• Cyclic Midcycle IMB – Small quantity of frank vaginal bleeding or discharge around 
midcycle, corresponding with ovulation due to a nadir in the oestradiol levels, is 
physiological, and is observed in 9% of women. 
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• Cyclic Pre or Postmenstrual IMB — Cyclical IMB that predictably occurs either early 
in the cycle (follicular phase) or late (luteal phase), and typically presents as very light 
vaginal bleeding for one or more days. 
• Acyclic IMB — When the IMB is not cyclical or predictable. 
 
Heavy Menstrual Bleeding (HMB) 
Heavy menstrual bleeding (HMB) is a sub-category of AUB and has a woman-centred 
approach to diagnosis.  Rather than using objective measurements of volume, traditionally 
defined as > 80 mL/cycle using the alkalin-hematin method or using PBAC (Pictorial Blood 
Assessment Chart) scores, NICE defines HMB as excessive menstrual blood loss (MBL) that 
interferes with the physical, social, emotional and/or material quality of life.  Some authors 
have found a good correlation between subjective and actual blood loss but not others.  A 
summary of terms that should no longer be used to describe menstrual bleeding patterns is 
listed in Table 3. 
[Insert Table 3] 
 
DEMOGRAPHICS 
AUB is a common and frequently debilitating condition for women worldwide.  It has 
clinical implications and a high cost for the healthcare system.  Uterine fibroids, a common 
cause of AUB are estimated to cost the US $5.9 to $34.4 billion annually.  AUB affects 14-
25% of women in the reproductive age group resulting in a large proportion of GP referrals 
within the NHS.  A recent HMB audit by the Royal College of Obstetricians and 
Gynaecologists (RCOG), assessing patient outcomes and experiences in England and Wales, 
reported that 1-year post referral, only 30% of women (including those managed with 
surgery) were ‘satisfied’ (or better) at the prospect of current menstrual symptoms 
 6 
 
continuing, as currently experienced, for the next five years.  Thus, menstrual problems 
represent a clinical area of unmet need.   
 
 
PALM-COEIN CLASSIFICATION OF AUB  
There are 9 main categories, Polyp; Adenomyosis; Leiomyoma; Malignancy and 
Hyperplasia; Coagulopathy; Ovulatory dysfunction; Endometrial; Iatrogenic; and Not 
otherwise classified.  In general, the components of the PALM group are discrete (structural) 
entities that may be identified visually with imaging techniques and/or histopathology, 
whereas the COEIN group is related to entities that are not defined by imaging or 
histopathology (non-structural). 
 
The term “DUB”, which was previously used as a diagnosis when there was no systemic or 
locally definable structural cause for AUB, should be abandoned.  These women generally 
have one or a combination of coagulopathy, a disorder of ovulation, or primary endometrial 
disorder—the last of which is most often a primary or secondary disturbance in local 
endometrial haemostasis. 
 
Polyps (AUB-P) 
Endometrial polyps are epithelial proliferations arising from the endometrial stroma and 
glands.  The majority are asymptomatic.  The reported prevalence of endometrial polyps 
varies widely depending on the definition of a polyp, the diagnostic method used, and the 
population studied.  Polyps maybe endometrial or endocervical.  
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Adenomyosis and AUB (AUB-A) 
Adenomyosis is defined as the presence of ectopic endometrial glands and stroma in the 
myometrium, although it remains a poorly understood entity.  The prevalence of 
adenomyosis is difficult to ascertain because of a wide variation in diagnostic criteria both 
with imaging modalities and with histology.  It has been estimated that histological 
confirmation of adenomyosis ranges from 5-70% of patients who undergo hysterectomy.  
 
Leiomyomas and AUB (AUB-L) 
Uterine fibroids (myomas, leiomyomas) are the most common benign tumours in women of 
reproductive age and present in almost 80% of all women by the age of 50.  The association 
between AUB and fibroids is complex and poorly understood, as women with fibroids may 
be asymptomatic.  There is a correlation between AUB and the degree of distortion and 
penetration of the uterine cavity associated with the fibroid(s).  Submucous fibroids are 
considered to be most commonly associated with AUB/HMB.  
 
Malignancy and hyperplasia (AUB-M) 
Endometrial hyperplasia and malignancy are important potential causes of AUB and must be 
considered in nearly all women of reproductive age.  Once identified, the pathology should 
be further sub-classified using the appropriate WHO or FIGO system.  In the UK, 
endometrial cancer is the fourth most common cancer in women.  Historically, endometrial 
cancer has rarely occurred in premenopausal women; however, with increasing obesity and 
rising prevalence of the metabolic syndrome, the endocrine-driven subset of endometrial 
malignancy has markedly increased in frequency. 
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Coagulopathy (AUB-C) 
High quality evidence demonstrates that approximately 13% of women with HMB have 
biochemically detectable systemic disorders of haemostasis, most often von Willebrand 
disease.  A structured approach to history taking as shown in Table 4 will identify 90% of 
women with systemic disorders of haemostasis.  
[Insert Table 4] 
 
HMB may occur with the use of anticoagulant drugs such as warfarin, heparin, and low 
molecular weight heparin.  There is impairment of the formation of an adequate “plug” or 
clot within the vascular lumen.  Originally the FIGO MDC determined that this type of 
iatrogenic AUB should be placed in the AUB-C category.  The 2018 update of the FIGO, 
PALM-COEIN classification system has moved AUB associated with anticoagulation into 
the category “AUB-I”. 
 
Ovulatory dysfunction (AUB-O) 
Ovulatory dysfunction (anovulation) is often secondary to other disorders resulting in 
hormonal fluctuations such as polycystic ovary syndrome, hypothyroidism, 
hyperprolactinemia, mental stress, obesity, anorexia, weight loss, or extreme exercise.  
Ovulatory dysfunction frequently occurs at the extremes of reproductive age: adolescence 
and the menopause.  In some instances, hormonal fluctuations may be iatrogenic, caused by 
sex steroids or drugs that impact dopamine metabolism.  The 2018 update of the FIGO, 
PALM-COEIN classification system recommends that therapies interfering with the H-P-O 
axis and are associated with AUB, now be placed in the “AUB-I” category. 
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Endometrial (AUB-E) 
AUB that occurs in the context of a structurally normal uterus with regular menstrual cycles 
in the absence of a coagulopathy is likely to represent a primary endometrial disorder of the 
mechanisms regulating local endometrial haemostasis.  Tests measuring such abnormalities 
are not currently available.  
 
Iatrogenic (AUB-I) 
Unscheduled endometrial bleeding that occurs during the use of sex steroid therapy is termed 
“breakthrough bleeding (BTB)” and is a major component of this classification.  It is likely 
that many episodes of unscheduled bleeding or BTB are related to reduced circulating 
hormone levels, secondary to compliance issues such as missed, delayed, or erratic use, use 
of anticonvulsants and antibiotics (e.g. rifampin and griseofulvin) and cigarette smoking. 
This may reduce levels of contraceptive steroids because of enhanced hepatic metabolism.  
Many women experience unscheduled vaginal spotting or bleeding in the first 3–6 months of 
use of the levonorgestrel-releasing intrauterine system (LNG-IUS) and should be 
appropriately counselled.  Indeed, all progestin-only contraceptive methods are associated 
with episodes of unscheduled bleeding in 20% of users and all women should be counselled 
about this side effect. 
 
Tricyclic antidepressants (e.g. amitriptyline and nortriptyline) and phenothiazines impact 
dopamine metabolism by reducing serotonin uptake and result in reduced inhibition of 
prolactin release.  This may result in anovulation and consequent AUB. As noted above, 
AUB associated with anticoagulant use, is now also included in this category as per the 2018 
FIGO, PALM-COEIN classification update. 
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Not “yet” classified [AUB-N; revised in 2018 to not “otherwise” classified] 
Entities such as chronic endometritis, arteriovenous malformations; or bleeding from a 
caesarean section scar defect or isthmocoele may be associated with or contribute to 
AUB/HMB. 
 
 
MANAGEMENT APPROACH TO AUB 
A structured history and other associated symptoms can indicate a potential underlying cause 
of AUB.  These may represent structural causes (AUB-L, AUB-P, AUB-A), iatrogenic AUB 
(AUB-I), and disorders of ovulation (AUB-O).  AUB-M should always be considered 
especially in women with a raised BMI, diabetes, hypertension, PCOS, age >45 years, 
nulliparity, late menopause, unopposed oestrogen exposure, tamoxifen use, family history of 
breast, colon, endometrial cancer e.g. Lynch syndrome or other risk factors for endometrial 
cancer.  As mentioned earlier, AUB-C may also be diagnosed with a targeted history.  Table 
5 summarises an appropriate history in women presenting with AUB. 
[Insert Table 5] 
 
 
INVESTIGATION IN AUB/HMB 
Table 6 summarises the investigations in women with HMB/AUB as per current NICE 
guidance. 
[Insert Table 6] 
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Management of AUB/HMB 
Management of women with AUB/HMB is complex with an interplay of several factors.  
This may include conservative treatment (a period of observation), medical or surgical 
treatment (excisional and non-excisional therapies), depending on the patient’s age, parity, 
cause of bleeding, co-existing morbidities, the desire for fertility preservation, impact on the 
quality of life and patient preference. 
 
Nonpharmacological management 
A careful explanation of the cause of AUB is essential and exclusion of pathology will often 
allay fears and provide reassurance, such that women may simply choose to monitor their 
menstrual cycles using a menstrual calendar.  Monitoring is made easy with the abundance of 
“apps” available on modern smart devices for this purpose. 
 
Regular exercise and maintenance of a healthy body mass index (BMI) should be 
recommended as a higher BMI is often associated with AUB-O.  Exercise and a healthy diet 
will also help limit iron deficiency anaemia, raise energy levels and improve quality of life. 
 
Pharmacological management 
Flow chart A, provides a simplified approach to women presenting with AUB/HMB and 
Table 7 provides a summary of the commonly used pharmacological methods used in treating 
women with AUB/HMB. 
[Insert Table 7] 
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FIBROIDS AND AUB/HMB 
An extremely common cause of AUB/HMB are fibroids (myomas, leiomyomas).  Uterine 
fibroids are the most common benign tumours in women of reproductive age.  Although 
hysterectomy offers a permanent solution to the complaint of AUB/HMB, a significant 
proportion of symptomatic fibroids are seen in younger women who desire uterine and or 
fertility preservation and hence medical treatments have an important role to play. 
 
Probably the most important medical therapy for management of fibroids in recent years are 
the selective progesterone receptor modulators (SPRMs). These SPRMs impart a tissue-
specific partial progesterone antagonist effect and act upon progesterone receptors in the 
endometrium and the underlying myometrial tissue. Ulipristal acetate (UPA) is the only 
SPRM specifically approved and commercialised to date for management of symptomatic 
uterine fibroids.  UPA controls HMB in over 90% of women, with an overall decrease in 
bleeding similar to GnRH agonist use but has a faster onset of amenorrhea usually within 10 
days.  Oestradiol levels are maintained in the mid-follicular phase range during treatment 
thereby reducing the menopausal symptoms. UPA does cause the benign endometrial 
changes described as PAEC (progesterone receptor modulator associated endometrial 
changes).  These changes are reversible after treatment discontinuation. 
 
UPA use was placed under review in February 2018 by the European Medicines Agency 
(EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) due to eight 
reports of serious liver injury, including cases of hepatic failure requiring liver 
transplantation, reported in Europe in women using UPA for uterine fibroids.  The up-to-date 
MHRA guidance in August 2018 following completion of the EMA review is available here - 
https://www.gov.uk/drug-safety-update/esmya-ulipristal-acetate-and-risk-of-serious-liver-
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injury-new-restrictions-to-use-and-requirements-for-liver-function-monitoring-before-
during-and-after-treatment 
Restricted indications and new contraindications for UPA use (August 2018) in the United 
Kingdom are summarised in Table 8.  Vilaprisan is a newer SPRM, currently under 
investigation. 
[Insert Table 8] 
 
 
NON-EXCISIONAL TREATMENT FOR AUB/HMB 
Endometrial ablation (second-generation) and transcervical resection of the endometrium 
(TCRE), represent non-excisional methods of treating AUB/HMB and offer an alternative to 
hysterectomy in women who have no desire for fertility preservation.  Both procedures are 
effective, and satisfaction rates are high.  Although hysterectomy is associated with longer 
operating, a longer recovery period and higher rates of postoperative complications, it offers 
permanent relief from heavy menstrual bleeding. 
 
Non-excisional treatment for fibroids include; Uterine Artery Embolisation (UAE).  Magnetic 
Resonance Imaging guided High Frequency Ultrasound (MRgFUS), Radiofrequency 
Volumetric Thermal Ablation (RFVTA), Laparoscopic or Vaginal Uterine Artery Ligation 
Laparoscopic thermomyolysis and Laparoscopic Cryomyolysis. 
 
 
SURGICAL TREATMENT FOR AUB/HMB 
It is beyond the scope of this article to discussion surgical treatments for individual causes of 
AUB/HMB (PALM – structural causes), but a brief summary is presented below in Table 9. 
[Insert Table 9] 
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CONCLUSION 
AUB is common and negatively impacts the quality of life of women worldwide and has 
clinical implications and high costs for the healthcare systems. The PALM-COEIN acronym 
maybe be used as a foundation of care; it improves the understanding of the causes of AUB, 
and in doing so facilitates effective history taking, examination, investigations and onward 
management.  A range of treatment options are available, which should be tailored to the 
woman’s individual need and the desire for uterine/fertility preservation, to reduced treatment 
failures, improve satisfaction rates and avoid the need for major excisional surgery. 
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booklet.pdf)  
MANAGEMENT OF AUB/HMB – CHART A 
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TABLES 
 
Table 1 – Parameters of the Normal Menstrual Cycle [Adapted from Munro et al, Int J 
Gynaecol Obstet 2018] 
 
Parameter Normal Limits (5th to 95th centile) 
Frequency of menses (days) 24 to 38 days 
 
 
Regularity (Cycle length) 
≤7 to 9 days 
Cycle length is the number of days from the 
first day of one menstrual cycle to the first 
day of the next. No more than seven to nine 
days difference between the shortest to 
longest cycles 
Duration (days of bleeding in a single 
menstrual period) 
≤8 days 
 
 
Volume (monthly blood loss) 
Clinical definition is subjective and 
defined as a volume of menstrual blood loss 
that does not 
interfere with a woman's physical, 
social, emotional, and/or quality 
of life 
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Table 2 - AUB Terminology Cycle [Adapted from Munro et al, Int J Gynaecol Obstet 
2018] 
 
Parameters Terminology Out with 5th to 95th centile 
Frequency of menses 
(days) 
  
  
Absent  Amenorrhoea – Primary or 
Secondary 
Infrequent >38 days 
Frequent <24 days 
  
 
  
Regularity (Cycle length) Irregular Shortest to longest cycle variation 
≥ 10 days 
Duration (days of 
bleeding in a single 
menstrual period) 
Prolonged > 8 days 
Volume (monthly blood 
loss) 
Heavy or 
light 
Subjectively defined 
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Table 3 – Abandoned Terminology 
 
Menorrhagia 
Metrorrhagia 
Dysfunctional Uterine Bleeding (DUB) 
Epimenorrhea and Epimenorrhagia 
Hypomenorrhea and Hypermenorrhea 
Polymenorrhea and Polymenorrhagia 
Menometrorrhagia 
Oligomenorrhea 
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Table 4 – Identifying women with AUB-C [Adapted from Kouides et al, Fertil Steril 
2005]  
 
Structured history—positive screen if 
(a) Excessive menstrual bleeding since menarche, or 
(b)  History of one of the following—postpartum haemorrhage, surgery-
related bleeding, or bleeding associated with dental work, or  
(c)  History of two or more of the following— bruising greater than 5 cm 
once or twice/ month, epistaxis once or twice/month, frequent gum 
bleeding, family history of bleeding symptoms.  
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Table 5 – Appropriate history in women with AUB 
 
HISTORY IN WOMEN WITH AUB  
Menstrual History 
• Menstrual calendar (frequency, 
duration, volume, regularity) 
• Duration of HMB/AUB 
symptoms 
• Impact on the quality of life 
(QoL) 
• Intermenstrual bleeding 
• Postcoital Bleeding 
• Age at menarche (if relevant) 
Associated Symptoms 
• Pain during periods 
(dysmenorrhea) 
• Chronic pelvic pain 
• Abnormal vaginal 
discharge 
• Pressure symptoms 
(constipation, urinary 
frequency) 
Sexual and Reproductive History 
• Parity and mode of birth 
• Need for fertility 
preservation 
• Need for contraception 
• Sexually transmitted 
infections (STIs) 
• Cervical smear history 
 
Personal History 
• Smoking 
• Alcohol 
• Systemic disorders 
• Drug history (pharmacological 
and recreational) 
• Occupation 
• Recent weight gain or loss 
• Coagulopathy screen (Table 4) 
Family history 
• Venous 
Thromboembolic events 
(VTE) 
• Cancer 
• Disorders of 
haemostasis 
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Table 6 – Investigations in women with AUB as per NICE guidance. 
 
INVESTIGATIONS FOR WOMEN WITH AUB/HMB 
TYPE SPECIFIC TEST INDICATION 
Blood tests Full Blood Count Baseline testing to exclude anaemia 
 Thyroid profile In women with symptoms of thyroid disease  
 Coagulation Screen In women who have HMB since the onset of their 
periods or those with personal or family history 
suggestive of a coagulation disorder. 
 Female Hormone profile Do not perform routinely 
 Serum Ferritin Do not perform routinely 
   
Histology Endometrial Sampling Rule out endometrial hyperplasia and or cancer. 
NICE (2018) proposes blind endometrial sampling 
should be avoided and performed in the context of 
hysteroscopy. 
   
Imaging Ultrasound Ultrasound (transvaginal) is the preferred method 
to rule out structural abnormalities e.g. fibroids, 
adenomyosis. If unacceptable, transabdominal 
ultrasound or magnetic resonance imaging (MRI) 
should be organised. 
 Hysteroscopy NICE (2018) suggests women should be offered 
vaginoscopically performed outpatient 
hysteroscopy in a “see and treat” setting, if their 
history suggests submucosal fibroids, polyps or 
endometrial pathology as a first line investigation. 
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Table 7 – Pharmacological management of AUB 
Therapy Evidence for use 
Tranexamic Acid (TXA) 
40% to 50% reduction in MBL per cycle. Antifibrinolytic treatment is better at 
improving MBL than other medical treatments, except for the levonorgestrel-releasing 
intrauterine system (LNG-IUS).  No evidence that side effects (including life‐
threatening blood clots) is increased compared to placebo or other treatments for HMB. 
TXA is particularly useful in women who either desire pregnancy immediately or for 
whom hormonal treatment is inappropriate. The drug is cost‐effective and improves 
health‐related quality of life. 
Non-steroidal anti-
inflammatory drugs 
(NSAIDs) 
Benefits are modest; although MBL is reduced, a proportion of women will still have 
objective HMB. Gastrointestinal effects, are less likely with mefenamic acid compared 
to other NSAIDs. Efficacy of NSAIDs is superseded by tranexamic acid and LNG IUS. 
Beneficial in women where dysmenorrhea is present with AUB/HMB. 
Levonorgestrel-releasing 
intrauterine system 
(LNG-IUS) 
Significant reduction in MBL from baseline in HMB in women, including selected 
women with fibroids as compared to standard oral treatments. More effective than oral 
medical therapies and results in better quality of life outcomes (QoL). Not as effective 
as hysterectomy in reducing MBL but improvements in QoL were similar. The role of 
the LNG-IUS as a treatment for HMB in primary care settings versus other medical 
treatments was demonstrated by the ECLIPSE study. 
Cyclical Progestogens 
(e.g. 
Medroxyprogesterone 
acetate or Norethisterone) 
Progestogens administered from day 15 or 19 to day 26 of the cycle offer no advantage 
over other medical therapies. Progestogen therapy for 21 days (day 5-26) of the cycle 
results in a significant reduction in menstrual blood loss (up to 80%), although less 
acceptable choice than LNG-IUS. 
Combined Oral 
Contraceptive Pill 
(COCP) 
COCP can provide cycle control and reduce menstrual blood loss (up to 50%), but there 
are not enough data to determine its value in comparison with other drugs. The COCP 
may be used in a triphasic or tricycling manner to reduce the number of menstrual 
 24 
 
 
 
  
bleeds to 3-4 per year. UKMEC criteria may be used to assess suitability 
(http://www.fsrh.org/ukmec/). 
Injectable progestogen, 
e.g. depot 
medroxyprogesterone 
acetate 
Intramuscular or subcutaneous injection of high dose progestogens (e.g., depot 
medroxyprogesterone acetate [DMPA]) can induce amenorrhea in up to 50% of users. 
Women may have a transient but reversible reduction in their bone mineral density with 
long-term use. 
Gonadotropin-releasing 
hormone agonists (IM, 
SC or intranasal) ± add-
back 
Excellent efficacy, with an amenorrhea rate of up to 90%. However, they are associated 
with very significant menopausal side effects secondary to oestrogen deficiency that 
limit routine or ad hoc use. Limitation of these side effects can be achieved with ‘add-
back’ hormone replacement therapy (HRT, e.g. Tibolone) usually introduced after 6 
months of use. 
Progesterone only pill 
(POP or Minipill) 
 POP is associated with irregular and unpredictable blood loss and it is not usually 
recommended as a primary treatment for AUB, unless other treatments have failed or 
are contraindicated. Desogestrel containing POPs may provide effective treatment in 
some women. 
Problem specific 
treatments 
It is beyond the scope of this article to discuss treatments for individual causes of 
AUB/HMB, e.g. AUB-C managed using DDVAP and/or Tranexamic acid. 
Acute AUB (non 
gestational) 
Although high quality evidence is limited in this group of women, both COCP and 
medroxyprogesterone acetate have similar efficacy. 
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Table 8 - Restricted indications and new contraindications for UPA use (August 2018) in the 
United Kingdom  
 
Indications 
• UPA is indicated for the intermittent treatment 
of moderate to severe symptoms of uterine 
fibroids in women of reproductive age who 
are not eligible for surgery 
• UPA is indicated for one course of pre-
operative treatment of moderate to severe 
symptoms of uterine fibroids in adult women 
of reproductive age 
• UPA treatment is to be initiated and 
supervised by a physician experienced in the 
diagnosis and treatment of uterine fibroids 
• UPA is contraindicated in women with 
underlying liver disorders  
 
 
Liver function monitoring 
• Before initiation of each treatment 
course: perform liver function tests; do 
not initiate UPA in women with 
baseline alanine transaminase (ALT) or 
aspartate aminotransferase (AST) more 
that 2-times the upper limit of normal 
[ULN] 
• During the first 2 UPA treatment 
courses: perform liver function tests 
every month. 
• For further treatment courses: perform 
liver function tests once before each 
new course and when clinically 
indicated.  
• At the end of each treatment course: 
perform liver function tests after 2–4 
weeks. Stop UPA treatment and closely 
monitor women with ALT or AST more 
than 3-times upper limit of normal; 
consider the need for specialist 
hepatology referral. 
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Table 9 – Surgical management of AUB 
 
Causes of AUB/HMB Surgical Treatment 
Polyp 
Avulsion (usually cervical polyps) 
Hysteroscopic resection or removal 
Adenomyosis 
Adenomyomectomy 
Hysterectomy 
Leiomyoma (Fibroids) 
Myomectomy 
Hysterectomy 
Consider pre-treatment with GnRH 
analogues or SPRMs 
Malignancy 
Often a combination of radical excisional 
surgery +/-radiotherapy+/- chemotherapy or 
palliative surgery. 
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SBA QUESTIONS 
A 46-year-old woman presents to the Gynaecology Clinic after treatment with 4 courses of 
Ulipristal acetate (UPA), which was commenced for heavy menstrual bleeding in association 
with a fibroid uterus. She completed her last course 1 week ago and is yet to have a menstrual 
bleed. Her ultrasound scan today suggests a reduction in the uterine size and fibroid size. Her 
endometrial thickness is 16 mm. She has been amenorrhoeic on the UPA treatment and feels 
well today. Which of the following statements is true? 
 
A. She may be offered another course of UPA after her 1 menstrual bleed 
B. She can be offered another course of UPA after her 2 menstrual bleeds 
C. She should be offered immediate endometrial sampling 
D. She should be offered immediate liver function tests 
E. She should be offered liver function tests in 2-4 weeks of completing UPA course 
Answer:  
Correct answer is E. Option D is false. 
UPA is currently licensed for use for 4 courses. So, options A and B are false.  
Benign endometrial thickening is known with UPA use – PAEC or Progesterone Receptor 
Modulator Associated Endometrial change. These changes are reversible upon 
discontinuation of UPA. In This patient should be rescanned after a menstrual bleed. If the 
endometrial thickness is MORE than 16 mm, endometrial sampling should be offered. Option 
C is hence false. 
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A 30-year para 1 with a BMI of 24, fit and well presents to the Gynaecology Clinic with 
abnormal uterine bleeding. She describes an irregular cycle to no pattern over the last 12 
months. Her cervical smear and STI screening tests are normal. Her pelvic ultrasound reveals 
a structurally normal uterus with a endometrial thickness of 4 mm with normal ovaries. She 
had a etonogestrel subdermal implant inserted 20 months ago for contraception after the birth 
of her child. She has been trialled on the mini pill, combined pill, tranexamic acid, 
norethisterone with no benefit. She is at the end of her tether and requests an ablation or 
hysterectomy. This is a difficult decision as her family isn’t complete. She has had an eating 
disorder as a child and does not wish any treatments that may cause weight gain. Which of 
the following management choices is best suited? 
A. GnRH analogues 
B. Depot Medroxyprogesterone acetate 
C. Removal of the etonogestrel subdermal implant 
D. Endometrial Biopsy 
E. Endometrial Ablation 
F. Hysterectomy with ovarian conservation 
Answer 
Correct answer is C, In the first instance this patient should be offered a “hormonal 
medication” free period as she has been trialled on a polytherapy of hormones with a 
etonogestrel subdermal implant in situ. This may be responsible for AUB-I. The etonogestrel 
subdermal implant by itself may be responsible for unscheduled bleeding in up to 20% of 
users. 
Options E and F are not suitable are the patient’s family isn’t complete. 
GnRH analogues are a short-term measure and should not be used ad hoc when the aetiology 
of AUB in unclear. Option A is incorrect. 
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Depot Medroxyprogesterone acetate is also a progestin and could contribute to AUB I. Also, 
DMPA is associated with weight gain. Option B is incorrect. 
The patient has no clear indication for endometrial sampling (age, thin ET on USS, normal 
BMI). Option D is incorrect in the first instance, however may need to be undertaken to 
further clarify AUB aetiology. 
 
